Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden. Bergvall N, Tambour M, Henriksson F, Fredrikson S J Med Econ. 2012 Dec 18. PMID: 23211038. Abstract CommentRecommendBookmarkWatch